Project Description
“I have a gut feeling…” – most of us have uttered that phrase or something like it – it’s a way of expressing something deeply perceived but not necessarily explainable in words.
Scientific advances have now put real meaning to the idea of a “gut feeling” through two related discoveries that will change how we think about disorders like Parkinson’s/Alzheimer’s disease and other brain conditions.
First, it’s become clear that the brain and the gastrointestinal tract (the “gut”) are in constant two-way communication, so changes in the brain are reflected in the gut, and vice versa, so that changes in the gut are reflected in changes in brain function. This constant dialogue is called the “gut-brain axis.”
But how do the gut and the brain communicate with each other?
That’s the second major discovery in recent years – and it relates to the enormous population of microbes living in an ecosystem in the gut – the gut microbiome.
Those microbes make specific molecules that they use to establish and maintain their homes in the gut. Most of those microbes and molecules are harmless to the human host, and indeed, many are helpful and even vital to our brain health and survival. In a balanced, healthy microbiome ecosystem, those beneficial microbes and molecules outweigh any deleterious ones, and we remain healthy.
But under conditions that disrupt the gut microbiome ecosystem, that balance is quickly lost. Bacteria that make molecules that promote inflammation, and “leaky gut” rapidly outgrow their more mild-mannered peers, resulting in a deluge of destructive molecules not just in the gut, but in the entire circulatory system, triggering widespread inflammation and undesirable immune system responses in the brain.
External causes of this disruption can be things like antibiotics, fast food diets, and certain infections. Internal causes that are only now being discovered include things like stress, anxiety, and injury to other organs, specifically to the brain. Thus, what happens in the brain is directly reflected in the gut microbiome.
So, if a disrupted molecular “milieu” in the gut is both a result and a cause of brain changes, that milieu becomes a treasure trove of biomarkers (molecules that, when measured, can tell us about the state of the gut-brain axis and specific brain disorders), and of drug targets (molecules that, when identified and blocked, can alter the milieu and tip the balance back towards a healthy brain).
This molecular approach is part of the science of “Systems Biology,” and it lies at the core of what Evimero is doing. Using advanced molecular identification methods coupled with powerful AI tools, we identify critical microbiome pathways – chains of molecular events that lead to undesirable health effects – and the specific molecules that drive them in undesirable directions. These molecules become our biomarkers for a particular brain or CNS condition, and many become therapeutic targets for drug discovery and development.
Our tool for both biomarker detection and therapies? Antibodies – these incredibly target-specific biological molecules can “stick” tightly to our target molecules when they are present in a stool sample or swab, and then disclose the presence (and even amount) of the target molecules as biomarkers. This kind of biomarker detection can help people with known risks for brain/CNS disorders monitor their microbiomes for a deleterious shift, identify those with a recent CNS injury through a simple fecal test, and provide other crucial information on the patient’s microbiome status.
Those same antibodies make perfect drug components for modifying that all-important molecular milieu and favoring a state of health and disease resistance. We are developing a line of Causal Microbiome Metaproteome Pathway Inhibitors (CMMPIs), drugs comprised of multiple antibodies that block the key molecules in critical microbiome pathways. Discovered using our proprietary AI modeling, CMPI drugs will be comprised of multiple individual antibodies, each blocking a different but related step in a deleterious microbiome pathway. These drugs, along with their companion diagnostics, will become invaluable assets in preventing, identifying, and treating disorders of the gut-brain axis like Parkinson’s and Alzheimer’s, major depression, anxiety, and more.